Research Report

Establishing a Systems Biology approach to drug discovery and therapy design: Physiomics Plc

Abstract

Steered by Professor David Fell of Oxford Brookes University, Physiomics plc, an Oxford-based biotechnology innovation company has, since 2008, firmly established itself as a leading light in systems biology approaches to drug discovery and latterly in therapy design, demonstrable through contracts with three major international pharmaceutical companies. Through its strong advocacy of this approach the sector has invested in and adopted new computational biology processes. As Physiomics has continued to grow, it has expanded its own specialist research team, in many cases recruiting scientists trained within Fell’s Brookes-based research group.

Attached files

Authors

Fell, D (Oxford Brookes University)

Oxford Brookes departments

Faculty of Health and Life Sciences\Department of Biological and Medical Sciences

Dates

Year of publication: 2013
Date of RADAR deposit: 2014-12-18

---

© Oxford Brookes University
Published by Oxford Brookes University

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License